GlassScriptPhysician profile
Daniel G Thielemann
NPI 1801107255
$1,803.58
in general payments reported to CMS, 2019-2025
19 companies · $506 in 2025
The $506 reported for 2025 was more than what a typical Sleep Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $337).
See the full distribution for Sleep Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $51.87 · 2021: $320 · 2022: $148 · 2023: $274 · 2024: $377 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,046 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,046.48 |
| Education | $110.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $773.89 | 2019-2025 | Xywav |
| Inspire Medical Systems, INC. | $184.57 | 2021-2025 | Inspire |
| Cvrx, INC. | $144.85 | 2022-2025 | Barostim Neo System |
| Harmony Biosciences LLC | $123.07 | 2020-2024 | Wakix |
| Janssen Pharmaceuticals, INC | $107.35 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $99.00 | 2021-2025 | Uptravi, Opsynvi, Opsumit |
| Endologix LLC | $89.99 | 2019 | |
| Abbott Laboratories | $67.28 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $37.15 | 2023-2025 | Lifevest |
| Pulmonx Corporation | $25.79 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Acutus Medical, INC. | $21.73 | 2021-2022 | |
| Inspiremd LTD | $21.41 | 2025 | Cguard Prime Carotid Stent System |
| Alnylam Pharmaceuticals INC. | $19.42 | 2022 | |
| Axsome Therapeutics, INC. | $19.23 | 2024 | Sunosi |
| Merck Sharp & Dohme LLC | $16.76 | 2025 | Verquvo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $13.28 | 2019 | |
| Novo Nordisk INC | $13.25 | 2022 | |
| 3b Medical, INC. | $13.25 | 2024 | Luna |
| Glaxosmithkline, LLC. | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Thielemann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.